Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information

Abstract Biopsy information and protein Prostate-Specific Antigen (PSA) levels are the most robust information available to oncologists worldwide to diagnose and decide therapies for prostate cancer patients. However, prostate cancer presents a high risk of recurrence, and the technologies used to e...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura E. Marin, Daniel I. Zavaleta-Guzman, Jessyca I. Gutierrez-Garcia, Daniel Racoceanu, Fanny L. Casado
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-01896-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861819387674624
author Laura E. Marin
Daniel I. Zavaleta-Guzman
Jessyca I. Gutierrez-Garcia
Daniel Racoceanu
Fanny L. Casado
author_facet Laura E. Marin
Daniel I. Zavaleta-Guzman
Jessyca I. Gutierrez-Garcia
Daniel Racoceanu
Fanny L. Casado
author_sort Laura E. Marin
collection DOAJ
description Abstract Biopsy information and protein Prostate-Specific Antigen (PSA) levels are the most robust information available to oncologists worldwide to diagnose and decide therapies for prostate cancer patients. However, prostate cancer presents a high risk of recurrence, and the technologies used to evaluate it demand more complex resources. This paper aims to predict Biochemical Recurrence (BCR) based on Whole Slide Images (WSI) of biopsies, Gleason scores, and PSA levels. A U-net model was used to segment phenotypic features and trained on images from the Prostate Cancer Grade Assessment (PANDA) database to segment tumorous regions from pre-processed and scored WSI of biopsies. Then, the model was tested on data from publicly available repositories achieving an Intersection over Union of 87%. Tissue features, Gleason scores, and PSA levels provided high accuracy and precision in classifying patients according to their risk of presenting recurrence, for any Gleason score sampled. The trained classifier model demonstrated a 79.2% relative accuracy, and a precision of 69.7% for patients experiencing recurrences before 24 months. Our results provide a robust, cost-efficient approach using already available information to predict the risk of BCR.
format Article
id doaj-art-8af6e045cf18492f888871a561059f8e
institution Kabale University
issn 2730-6011
language English
publishDate 2025-02-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-8af6e045cf18492f888871a561059f8e2025-02-09T12:43:32ZengSpringerDiscover Oncology2730-60112025-02-0116111610.1007/s12672-025-01896-7Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available informationLaura E. Marin0Daniel I. Zavaleta-Guzman1Jessyca I. Gutierrez-Garcia2Daniel Racoceanu3Fanny L. Casado4Institute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del PeruInstitute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del PeruInstitute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del PeruSorbonne University, Paris Brain Institute, CNRS, Inria, Inserm, AP-HPInstitute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del PeruAbstract Biopsy information and protein Prostate-Specific Antigen (PSA) levels are the most robust information available to oncologists worldwide to diagnose and decide therapies for prostate cancer patients. However, prostate cancer presents a high risk of recurrence, and the technologies used to evaluate it demand more complex resources. This paper aims to predict Biochemical Recurrence (BCR) based on Whole Slide Images (WSI) of biopsies, Gleason scores, and PSA levels. A U-net model was used to segment phenotypic features and trained on images from the Prostate Cancer Grade Assessment (PANDA) database to segment tumorous regions from pre-processed and scored WSI of biopsies. Then, the model was tested on data from publicly available repositories achieving an Intersection over Union of 87%. Tissue features, Gleason scores, and PSA levels provided high accuracy and precision in classifying patients according to their risk of presenting recurrence, for any Gleason score sampled. The trained classifier model demonstrated a 79.2% relative accuracy, and a precision of 69.7% for patients experiencing recurrences before 24 months. Our results provide a robust, cost-efficient approach using already available information to predict the risk of BCR.https://doi.org/10.1007/s12672-025-01896-7Prostate cancerBiochemical recurrenceU-Net architectureGleason scoreWhole slide histopathology imageHematoxylin and Eosin staining
spellingShingle Laura E. Marin
Daniel I. Zavaleta-Guzman
Jessyca I. Gutierrez-Garcia
Daniel Racoceanu
Fanny L. Casado
Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
Discover Oncology
Prostate cancer
Biochemical recurrence
U-Net architecture
Gleason score
Whole slide histopathology image
Hematoxylin and Eosin staining
title Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
title_full Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
title_fullStr Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
title_full_unstemmed Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
title_short Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
title_sort prediction of biochemical prostate cancer recurrence from any gleason score using robust tissue structure and clinically available information
topic Prostate cancer
Biochemical recurrence
U-Net architecture
Gleason score
Whole slide histopathology image
Hematoxylin and Eosin staining
url https://doi.org/10.1007/s12672-025-01896-7
work_keys_str_mv AT lauraemarin predictionofbiochemicalprostatecancerrecurrencefromanygleasonscoreusingrobusttissuestructureandclinicallyavailableinformation
AT danielizavaletaguzman predictionofbiochemicalprostatecancerrecurrencefromanygleasonscoreusingrobusttissuestructureandclinicallyavailableinformation
AT jessycaigutierrezgarcia predictionofbiochemicalprostatecancerrecurrencefromanygleasonscoreusingrobusttissuestructureandclinicallyavailableinformation
AT danielracoceanu predictionofbiochemicalprostatecancerrecurrencefromanygleasonscoreusingrobusttissuestructureandclinicallyavailableinformation
AT fannylcasado predictionofbiochemicalprostatecancerrecurrencefromanygleasonscoreusingrobusttissuestructureandclinicallyavailableinformation